Patents by Inventor Alessandro Boezio

Alessandro Boezio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240190855
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of CDK enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 13, 2024
    Inventors: Alexander M. Taylor, Timothy F. Briggs, Nicolas A. Pabon, Jing He, Andre Lescarbeau, Alessandro Boezio, Catherine A. Evans, Cary Griffin Fridrich, Brian P. Kelley, Elaine B. Krueger, Ravi Kurukulasuriya, Thomas H. McLean
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20240158372
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: August 17, 2023
    Publication date: May 16, 2024
    Inventors: Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 11780826
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: October 10, 2023
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent Dimassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • FGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230104574
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 12, 2020
    Publication date: April 6, 2023
    Inventors: Bakary-Barry TOURÉ, Heike SCHOENHERR, Alexander M. TAYLOR, Fabrizio GIORDANETTO, Demetri T. MOUSTAKAS, Thomas H. MCLEAN, Brandi M. HUDSON, Mary M. MADER, Pelin AYAZ, Dina A. SHARON, Ravi KURUKULASURIYA, Alessandro BOEZIO
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20220281850
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 8, 2022
    Inventors: Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 11299479
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 12, 2022
    Assignees: CYTOKINETICS, INC., AMGEN INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 10899746
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 26, 2021
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Bisamide sarcomere activating compounds and uses therof
    Patent number: 10723720
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 28, 2020
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20200223829
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, JR., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20200223830
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, JR., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Pyridine sulfonamides
    Patent number: 10668067
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 2, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, John R. Butler, Benjamin Charles Milgram, Gwenaella Rescourio, Alessandro Boezio, Brian Andrew Sparling, Daniel La
  • Bicyclic ketone sulfonamide compounds
    Patent number: 10472356
    Abstract: The present invention provides compounds of Formula (I), wherein: as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 12, 2019
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Benjamin Charles Milgram, Thomas Dineen, John Stellwagen, Angel Guzman-Perez, Alessandro Boezio, Issac E. Marx
  • PYRIDINE SULFONAMIDES
    Publication number: 20190167682
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: July 20, 2017
    Publication date: June 6, 2019
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, John R. BUTLER, Benjamin Charles MILGRAM, Gwenaella RESCOURIO, Alessandro BOEZIO, Brian Andrew SPARLING, Daniel LA
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20190077793
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: September 13, 2018
    Publication date: March 14, 2019
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, JR., Richard Vargas, John Yeoman, Hanmo Zhang
  • BICYCLIC KETONE SULFONAMIDE COMPOUNDS
    Publication number: 20180051021
    Abstract: The present invention provides compounds of Formula (I), wherein: as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: March 2, 2016
    Publication date: February 22, 2018
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, Benjamin Charles MILGRAM, Thomas DINEEN, John STELLWAGEN, Angel GUZMAN-PEREZ, Alessandro BOEZIO, Issac E. MARX
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9458152
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: October 4, 2016
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgram, Hanh Nho Nguyen, Emily Anne Peterson, Karina R. Vaida, Brian Sparling
  • Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
    Patent number: 9346798
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 24, 2016
    Assignee: AMGEN INC.
    Inventors: Christiane Boezio, Alessandro Boezio, Howard Bregman, Nagasree Chakka, James R. Coats, Katrina Woodin Copeland, Erin F. Dimauro, Thomas Dineen, Hua Gao, Daniel La, Isaac E. Marx, Hanh Nho Nguyen, Emily Anne Peterson, Matthew Weiss
  • BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
    Publication number: 20160046626
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: October 22, 2015
    Publication date: February 18, 2016
    Inventors: Matthew WEISS, Alessandro BOEZIO, Christiane BOEZIO, John R. BUTLER, Margaret Yuhua CHU-MOYER, Erin F. DIMAURO, Thomas DINEEN, Russell GRACEFFA, Angel GUZMAN-PEREZ, Hongbing HUANG, Charles KREIMAN, Daniel LA, Isaac E. MARX, Benjamin Charles MILGRAM, Hanh Nho NGUYEN, Emily Anne PETERSON, Karina R. VAIDA, Brian SPARLING
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9212182
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2015
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgrim, Hanh Nho Nguyen, Emily Peterson, Karina Romero, Brian Sparling
  • Fused heterocyclic derivatives and methods of use
    Patent number: 9066954
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: June 30, 2015
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, David Bauer, Steven Bellon, Christiane M. Bode, Shon Booker, Alessandro Boezio, Deborah Choquette, Derin D'Amico, Jean-Christophe Harmange, Satoko Hirai, Randall W. Hungate, Tae-Seong Kim, Richard T. Lewis, Longbin Liu, Julia W. Lohman, Mark H. Norman, Michele Potashman, Aaron C. Siegmund, Stephanie K. Springer, Markian Stec, Ning Xi, Kevin Yang